Related Experiment Videos
[Clinical study on 9,3"-diacetylmidecamycin in the field of pediatrics (author's transl)]
Insights
9,3"-diacetylmidecamycin (MOM) is a novel macrolide antibiotic showing promising clinical efficacy. MOM demonstrated good tolerability and effectiveness in pediatric patients, with notable eradication rates for Streptococcus and pertussis. Further research is warranted.
Area of Science:
- Pharmacology
- Clinical Microbiology
- Pediatrics
Background:
- Midecamycin is a macrolide antibiotic.
- 9,3"-diacetylmidecamycin (MOM) is a novel derivative of midecamycin.
- This study investigates the clinical efficacy and safety of MOM in pediatric patients.
Observation:
- Serum concentrations of MOM were evaluated in a pediatric patient following oral administration of dry syrup and fine granules at varying doses.
- Clinical efficacy was assessed in 25 children treated with MOM dry syrup for various infections.
- Bacteriological eradication rates for Group A Streptococcus and clinical outcomes for pertussis, acute bronchitis, and Mycoplasma pneumonia were recorded.
Findings:
- MOM dry syrup demonstrated detectable serum concentrations up to 2 hours post-administration, with higher doses yielding higher concentrations.
- The overall efficacy rate for MOM dry syrup was 68.75% in pediatric patients.
- MOM showed an eradication rate of 9.09% for Group A Streptococcus and eradicated pertussis in 6 cases. Clinical responses varied for other infections.
- No significant clinical side effects or abnormal laboratory findings were observed during the study.
Implications:
- MOM exhibits favorable pharmacokinetic properties and a good safety profile in pediatric populations.
- The antibiotic shows potential for treating bacterial infections, including those caused by Group A Streptococcus and pertussis.
- Further clinical trials are recommended to establish MOM's therapeutic role and optimal dosing regimens.
Abstract:
We have studied clinically on 9,3"-diacetylmidecamycin (MOM), a new macrolide antibiotic derived from midecamycin. The following results were obtained. 1) Serum concentration. To the the same child weighing 15 kg and aged 4 years, the MOM dry syrup was administered orally at single doses of 150 mg (10 mg/kg) and 300 mg (20 mg/kg) and then the MDM fine granules at a single dose of 300 mg (20 mg/kg). At dosages of 10 mg/kg and 20 mg/kg of MOM dry syrup and 20 mg/kg of MDM fine granules, the serum concentrations were 0.5 microgram/ml, 0.8 microgram/ml and not detectable (N.D.) respectively, at 45 minutes after administration; 0.4, 0.6 and N.D. at 1 hour; 0.12; 0.2 and N.D, at 2 hours; N.D., less than 0.1, N.D. at 4 hours; N.D. in all the cases at 6 hours. 2) Clinical results. MOM dry syrup was administered to 25 children. The efficacy rate was 68.75% except for 1 dropout case and the elimination rate of 11 isolated strains of group A Streptococcus was 9.09% in 16 cases of scarlet fever and 1 of acute pharyngitis caused by group A Streptococcus. With 6 cases of pertussis were eradicated. The clinical response to 1 with acute bronchitis and 1 with Mycoplasma pneumonia were good and poor respectively. 3) Side effect. No clinical side effect and abnormal laboratory findings were observed in any of the 25 cases administered MOM dry syrup.